Literature DB >> 10408863

Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes.

P M De Angelis1, O P Clausen, A Schjølberg, T Stokke.   

Abstract

Comparative genomic hybridization (CGH) is used to detect amplified and/or deleted chromosomal regions in tumours by mapping their locations on normal metaphase chromosomes. Forty-five sporadic colorectal carcinomas were screened for chromosomal aberrations using direct CGH. The median number of chromosomal aberrations per tumour was 7.0 (range 0-19). Gains of 20q (67%) and losses of 18q (49%) were the most frequent aberrations. Other recurrent gains of 5p, 6p, 7, 8q, 13q, 17q, 19, X and losses of 1p, 3p, 4, 5q. 6q, 8p, 9p, 10, 15q, 17p were found in > 10% of colorectal tumours. High-level gains (ratio > 1.5) were seen only on 8q, 13q, 20 and X, and only in DNA aneuploid tumours. DNA aneuploid tumours had significantly more chromosomal aberrations (median number per tumour of 9.0) compared to diploid tumours (median of 1.0) (P < 0.0001). The median numbers of aberrations seen in DNA hyperdiploid and highly aneuploid tumours were not significantly different (8.5 and 11.0 respectively; P = 0.58). Four tumours had no detectable chromosomal aberrations and these were DNA diploid. A higher percentage of tumours from male patients showed Xq gain and 18q loss compared to tumours from female patients (P = 0.05 and 0.01 respectively). High tumour S phase fractions were associated with gain of 20q13 (P = 0.03), and low tumour apoptotic indices were associated with loss of 4q (P = 0.05). Tumours with TP53 mutations had more aberrations (median of 9.0 per tumour) compared to those without (median of 2.0) (P = 0.002), and gain of 8q23-24 and loss of 18qcen-21 were significantly associated with TP53 mutations (P = 0.04 and 0.02 respectively). Dukes' C/D stage tumours tended to have a higher number of aberrations per tumour (median of 10.0) compared to Dukes' B tumours (median of 3.0) (P = 0.06). The low number of aberrations observed in DNA diploid tumours compared to aneuploid tumours suggests that genomic instability and possible growth advantages in diploid tumours do not result from acquisition of gross chromosomal aberrations but rather from selection for other types of mutations. Our study is consistent with the idea that these two groups of tumours evolve along separate genetic pathways and that gross genomic instability is associated with TP53 gene aberrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408863      PMCID: PMC2362312          DOI: 10.1038/sj.bjc.6690388

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry.

Authors:  Y Remvikos; P Laurent-Puig; R J Salmon; G Frelat; B Dutrillaux; G Thomas
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

2.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

3.  Multiple genetic alterations in distal and proximal colorectal cancer.

Authors:  O Delattre; S Olschwang; D J Law; T Melot; Y Remvikos; R J Salmon; X Sastre; P Validire; A P Feinberg; G Thomas
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

Review 4.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

5.  Model for the genetic evolution of human solid tumors.

Authors:  S E Shackney; C A Smith; B W Miller; D R Burholt; K Murtha; H R Giles; D M Ketterer; A A Pollice
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

6.  DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.

Authors:  S H Bigner; R Bjerkvig; O D Laerum; L H Muhlbaier; D D Bigner
Journal:  Anal Quant Cytol Histol       Date:  1987-10       Impact factor: 0.302

7.  Clonal analysis of human colorectal tumors.

Authors:  E R Fearon; S R Hamilton; B Vogelstein
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

8.  Chromosome 5 allele loss in human colorectal carcinomas.

Authors:  E Solomon; R Voss; V Hall; W F Bodmer; J R Jass; A J Jeffreys; F C Lucibello; I Patel; S H Rider
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

9.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N I Nissen
Journal:  Cytometry       Date:  1983-03

Review 10.  Genetic pathways in colorectal cancer.

Authors:  M Ilyas; I P Tomlinson
Journal:  Histopathology       Date:  1996-05       Impact factor: 5.087

View more
  35 in total

1.  Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway.

Authors:  N J Hawkins; P Gorman; I P Tomlinson; P Bullpitt; R L Ward
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.

Authors:  Malin Lando; Christina S Fjeldbo; Saskia M Wilting; Barbara C Snoek; Eva-Katrine Aarnes; Malin F Forsberg; Gunnar B Kristensen; Renske Dm Steenbergen; Heidi Lyng
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

3.  Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas.

Authors:  Silke Lassmann; Roland Weis; Frank Makowiec; Jasmine Roth; Mihai Danciu; Ulrich Hopt; Martin Werner
Journal:  J Mol Med (Berl)       Date:  2006-12-02       Impact factor: 4.599

4.  Analysis of allelic imbalance in patients with colorectal cancer according to stage and presence of synchronous liver metastases.

Authors:  J C Weber; A Schneider; S Rohr; H Nakano; P Bachellier; A Méchine; G Hamel; M Kanor; M P Chenard; M P Gaub; P Oudet; C Meyer; D Jaeck
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

5.  CHST7 Gene Methylation and Sex-Specific Effects on Colorectal Cancer Risk.

Authors:  Haoran Bi; Yupeng Liu; Rui Pu; Tingting Xia; Hongru Sun; Hao Huang; Lei Zhang; Yuanyuan Zhang; Ying Liu; Jing Xu; Jiesheng Rong; Yashuang Zhao
Journal:  Dig Dis Sci       Date:  2019-02-28       Impact factor: 3.199

6.  CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Jeroen A M Beliën; Meike de Wit; Pien M Delis-van Diemen; Marianne Tijssen; Mark A van de Wiel; Fredrik Pontén; Gerrit A Meijer; Remond J A Fijneman
Journal:  Cell Oncol (Dordr)       Date:  2012-06-19       Impact factor: 6.730

7.  Drosophila C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways.

Authors:  Renee D Read; Erika A Bach; Ross L Cagan
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers.

Authors:  E Burum-Auensen; P M DeAngelis; A R Schjølberg; J Røislien; O Mjåland; O P F Clausen
Journal:  Cell Prolif       Date:  2008-08       Impact factor: 6.831

10.  p53 suppresses structural chromosome instability after mitotic arrest in human cells.

Authors:  W B Dalton; B Yu; V W Yang
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.